Jagsonpal Pharma Board Meeting on July 29 to Approve Q1 FY27 Results

Jagsonpal Pharmaceuticals Ltd has announced that its Board of Directors will convene on July 29, 2026. The primary agenda item for this meeting is to consider and approve the unaudited financial results for the first quarter ended June 30, 2026. Additionally, the company confirmed that the trading window for its securities will remain closed until July 31, 2026, as previously intimated on June 26, 2026. This announcement is made in compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.